Sinco Pharmaceuticals Holdings Limited
兴科蓉医药控股有限公司
(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 6833)

PROFIT WARNING

This announcement is made by Sinco Pharmaceuticals Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and potential investors of the Company that based on the information currently available to the Board, the Group is expected to record an increase of around 50% in total comprehensive loss for the year ended 31 December 2018 (the "**Reporting Period**"), as compared to that of 2017 (2017: RMB185.9 million). Such expected loss is mainly attributable to (i) the loss on disposal of the inventories relating to the Group's non-major products, since the Group had taken steps to terminate or suspend the business of some of its non-major products based on a view to adapt to the market changes in the pharmaceutical industry in the People's Republic of China (the "**PRC**"); and (ii) the significant increase on the selling and distribution expenses related to the market development and sales promotion activities performed by the Group during the Reporting Period.

The information contained in this announcement is based only on a preliminary assessment by the Board with reference to the information currently available to it, including the latest unaudited consolidated management accounts of the Group, and is not based on any information or figures which have been audited, confirmed or reviewed by the auditors or the audit committee of the Company. As at the date of this announcement, the audited consolidated results of the Group for the Reporting Period have not yet been finalised and are subject to adjustments.

The annual results announcement of the Group for the Reporting Period is expected to be published by the end of March 2019. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 11 March 2019

As at the date of this announcement, the executive Directors are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive Directors are Mr. Wang Qing, Mr. Liu Wenfang and Mr. Lau Ying Kit.